FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610404324> ?p ?o ?g. }

• W2610404324 endingPage "7" @default.
• W2610404324 startingPage "1" @default.
• W2610404324 abstract "Esophageal cancer is the eighth most common cancer worldwide. It is the fourth most common cause of cancer death in China and esophageal squamous cell carcinoma (ESCC) is the most prevalent histologic type. Many clinical trials have explored the value of neoadjuvant or adjuvant chemoradiation therapy in potentially resectable ESCC; however, these studies have produced conflicting results. This retrospective study was performed to investigate whether patients with resectable stage II/III ESCC should receive neoadjuvant or adjuvant therapy in addition to surgery. A review of stage II/III thoracic ESCC patients who underwent esophagectomy and either neoadjuvant or adjuvant chemoradiation was performed. Chemotherapy regimen consisted of cisplatin 75 mg/m2 divided into 3 days and fluorouracil 500 mg/m2 on days 1 to 5. The patients who underwent neoadjuvant therapy were treated with one cycle of chemotherapy concurrently with radiotherapy (40 Gy in 20 fractions, 5 days/week), and those receiving adjuvant therapy were treated with two cycles of chemotherapy concurrently with radiotherapy (46-50 Gy in 23-25 fractions, 5 days/week). A total of 122 patients met inclusion criteria, of which 49 underwent neoadjuvant chemoradiation and 73 underwent adjuvant chemoradiation. Median follow up was 36.5 months. The median survival times and 3, 5-year overall survival (OS) rates for the neoadjuvant and adjuvant groups were 39.3 versus 31.5 months, and 53.0%, 45.7% versus 42.9%, 29.7%, respectively (P = 0.091). For the patients with stage III ESCC, the median survival times and 5-year OS rates for the neoadjuvant and adjuvant groups were 39.3 versus 21.3 months, and 43.4% versus 21.0%, respectively (P = 0.021). Among lymph node-positive patients, the median survival times and 5-year OS rates for the neoadjuvant and adjuvant groups were 55.6 versus 23.7 months, and 43.0% versus 25.7%, respectively (P = 0.085). The incidence of perioperative and postoperative complications was comparable between the two groups (P > 0.05). For patients with resectable stage II/III ESCC, neoadjuvant chemoradiation does not increase postoperative complications and is associated with a trend toward better OS when compared to adjuvant chemoradiation." @default.
• W2610404324 created "2017-05-12" @default.
• W2610404324 creator A5020141736 @default.
• W2610404324 creator A5051976562 @default.
• W2610404324 creator A5068851869 @default.
• W2610404324 creator A5075179583 @default.
• W2610404324 creator A5076032164 @default.
• W2610404324 creator A5076776163 @default.
• W2610404324 creator A5081884581 @default.
• W2610404324 creator A5088745232 @default.
• W2610404324 creator A5091884940 @default.
• W2610404324 date "2017-05-05" @default.
• W2610404324 modified "2023-09-27" @default.
• W2610404324 title "Neoadjuvant versus adjuvant chemoradiation for stage II–III esophageal squamous cell carcinoma: a single institution experience*" @default.
• W2610404324 cites W1556798158 @default.
• W2610404324 cites W1584204846 @default.
• W2610404324 cites W1978302254 @default.
• W2610404324 cites W2022141909 @default.
• W2610404324 cites W2040085451 @default.
• W2610404324 cites W2073132357 @default.
• W2610404324 cites W2092960407 @default.
• W2610404324 cites W2111674123 @default.
• W2610404324 cites W2122166737 @default.
• W2610404324 cites W2122955480 @default.
• W2610404324 cites W2140625837 @default.
• W2610404324 cites W2154444715 @default.
• W2610404324 cites W2156978799 @default.
• W2610404324 doi "https://doi.org/10.1093/dote/dox016" @default.
• W2610404324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28475725" @default.
• W2610404324 hasPublicationYear "2017" @default.
• W2610404324 type Work @default.
• W2610404324 sameAs 2610404324 @default.
• W2610404324 citedByCount "12" @default.
• W2610404324 countsByYear W26104043242018 @default.
• W2610404324 countsByYear W26104043242019 @default.
• W2610404324 countsByYear W26104043242020 @default.
• W2610404324 countsByYear W26104043242021 @default.
• W2610404324 countsByYear W26104043242022 @default.
• W2610404324 crossrefType "journal-article" @default.
• W2610404324 hasAuthorship W2610404324A5020141736 @default.
• W2610404324 hasAuthorship W2610404324A5051976562 @default.
• W2610404324 hasAuthorship W2610404324A5068851869 @default.
• W2610404324 hasAuthorship W2610404324A5075179583 @default.
• W2610404324 hasAuthorship W2610404324A5076032164 @default.
• W2610404324 hasAuthorship W2610404324A5076776163 @default.
• W2610404324 hasAuthorship W2610404324A5081884581 @default.
• W2610404324 hasAuthorship W2610404324A5088745232 @default.
• W2610404324 hasAuthorship W2610404324A5091884940 @default.
• W2610404324 hasConcept C121608353 @default.
• W2610404324 hasConcept C126322002 @default.
• W2610404324 hasConcept C141071460 @default.
• W2610404324 hasConcept C143998085 @default.
• W2610404324 hasConcept C146357865 @default.
• W2610404324 hasConcept C151730666 @default.
• W2610404324 hasConcept C2776694085 @default.
• W2610404324 hasConcept C2777297899 @default.
• W2610404324 hasConcept C2777982462 @default.
• W2610404324 hasConcept C2778292576 @default.
• W2610404324 hasConcept C2778424827 @default.
• W2610404324 hasConcept C2779742542 @default.
• W2610404324 hasConcept C2780456651 @default.
• W2610404324 hasConcept C2781413609 @default.
• W2610404324 hasConcept C509974204 @default.
• W2610404324 hasConcept C530470458 @default.
• W2610404324 hasConcept C71924100 @default.
• W2610404324 hasConcept C86803240 @default.
• W2610404324 hasConceptScore W2610404324C121608353 @default.
• W2610404324 hasConceptScore W2610404324C126322002 @default.
• W2610404324 hasConceptScore W2610404324C141071460 @default.
• W2610404324 hasConceptScore W2610404324C143998085 @default.
• W2610404324 hasConceptScore W2610404324C146357865 @default.
• W2610404324 hasConceptScore W2610404324C151730666 @default.
• W2610404324 hasConceptScore W2610404324C2776694085 @default.
• W2610404324 hasConceptScore W2610404324C2777297899 @default.
• W2610404324 hasConceptScore W2610404324C2777982462 @default.
• W2610404324 hasConceptScore W2610404324C2778292576 @default.
• W2610404324 hasConceptScore W2610404324C2778424827 @default.
• W2610404324 hasConceptScore W2610404324C2779742542 @default.
• W2610404324 hasConceptScore W2610404324C2780456651 @default.
• W2610404324 hasConceptScore W2610404324C2781413609 @default.
• W2610404324 hasConceptScore W2610404324C509974204 @default.
• W2610404324 hasConceptScore W2610404324C530470458 @default.
• W2610404324 hasConceptScore W2610404324C71924100 @default.
• W2610404324 hasConceptScore W2610404324C86803240 @default.
• W2610404324 hasIssue "7" @default.
• W2610404324 hasLocation W26104043241 @default.
• W2610404324 hasLocation W26104043242 @default.
• W2610404324 hasOpenAccess W2610404324 @default.
• W2610404324 hasPrimaryLocation W26104043241 @default.
• W2610404324 hasRelatedWork W2404042595 @default.
• W2610404324 hasRelatedWork W2411066725 @default.
• W2610404324 hasRelatedWork W2415184292 @default.
• W2610404324 hasRelatedWork W2431147081 @default.
• W2610404324 hasRelatedWork W2919388994 @default.
• W2610404324 hasRelatedWork W2921693759 @default.
• W2610404324 hasRelatedWork W2967409375 @default.
• W2610404324 hasRelatedWork W3044905487 @default.
• W2610404324 hasRelatedWork W4226465080 @default.

• next